Global Bronchiectasis Drugs Market
Global Bronchiectasis Drugs Market

Bronchiectasis Drugs Comprehensive Study by Type (Antibiotics, Expectorants, Beta-Agonists, Inhaled Corticosteroids, Others), Indication (Cylindrical Bronchiectasis, Varicose Bronchiectasis, Cystic Bronchiectasis), Distribution (Third Party Websites, Hospital Dispensaries, Retail Pharmacies) Players and Region - Global Market Outlook to 2026

Bronchiectasis Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2026  

Jul 2021 Edition 234 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Bronchiectasis Drugs Market Scope
Bronchitis has a significant global burden of illness, disproportionately affecting poor nations and vulnerable people. Bronchiectasis, or the damage and dilatation of the airways, is caused by a self-perpetuating cycle of airway inflammation, infection, and obstruction, which results in significant morbidity and death. Despite the fact that various treatments have been explored to target each of these three components, as well as the illnesses that both cause and result from bronchiectasis, few randomised, placebo-controlled studies have been conducted.

The Bronchiectasis Drugs market study is segmented by Type (Antibiotics, Expectorants, Beta-Agonists, Inhaled Corticosteroids and Others) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Bronchiectasis Drugs market throughout the predicted period.

Endo International Plc (Ireland), Reckitt Benckiser Group Plc (United Kingdom), GlaxoSmithKline Plc (United Kingdom), Neopharma LLC (United Arab Emirates), Pfizer Inc. (United States), Santhera Pharmaceuticals Holding AG (Switzerland), Bayer AG (Germany), Insmed Inc. (United States), Aradigm Corp. (United States), Zambon S.p.A. (Italy) and Alitair Pharmaceuticals Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Bronchiectasis Drugs market by Type, Application and Region.

On the basis of geography, the market of Bronchiectasis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Technical Progress in Medical Industry

Market Drivers
  • Prevalence of Bronchiectasis & Severe Acute Respiratory Syndrome (SARS)
  • Rising Geriatric Population

Opportunities
  • Unexplored Markets
  • Heavy Investments in Healthcare Research & Development

Restraints
  • Side Effects and Adverse Reactions

Challenges
  • Regulatory Approval


Key Target Audience
Pharmaceutical Manufactures, New Entrants and Investors, Pharmaceutical Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Bronchiectasis Drugs Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Antibiotics
  • Expectorants
  • Beta-Agonists
  • Inhaled Corticosteroids
  • Others
By Indication
  • Cylindrical Bronchiectasis
  • Varicose Bronchiectasis
  • Cystic Bronchiectasis

By Distribution
  • Third Party Websites
  • Hospital Dispensaries
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Bronchiectasis & Severe Acute Respiratory Syndrome (SARS)
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bronchiectasis Drugs, by Type, Indication, Distribution and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Bronchiectasis Drugs (Value)
      • 5.2.1. Global Bronchiectasis Drugs by: Type (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Expectorants
        • 5.2.1.3. Beta-Agonists
        • 5.2.1.4. Inhaled Corticosteroids
        • 5.2.1.5. Others
      • 5.2.2. Global Bronchiectasis Drugs by: Indication (Value)
        • 5.2.2.1. Cylindrical Bronchiectasis
        • 5.2.2.2. Varicose Bronchiectasis
        • 5.2.2.3. Cystic Bronchiectasis
      • 5.2.3. Global Bronchiectasis Drugs by: Distribution (Value)
        • 5.2.3.1. Third Party Websites
        • 5.2.3.2. Hospital Dispensaries
        • 5.2.3.3. Retail Pharmacies
      • 5.2.4. Global Bronchiectasis Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Bronchiectasis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Endo International Plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Reckitt Benckiser Group Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Neopharma LLC (United Arab Emirates)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Santhera Pharmaceuticals Holding AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Insmed Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Aradigm Corp. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zambon S.p.A. (Italy)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Alitair Pharmaceuticals Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Bronchiectasis Drugs Sale, by Type, Indication, Distribution and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bronchiectasis Drugs (Value)
      • 7.2.1. Global Bronchiectasis Drugs by: Type (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Expectorants
        • 7.2.1.3. Beta-Agonists
        • 7.2.1.4. Inhaled Corticosteroids
        • 7.2.1.5. Others
      • 7.2.2. Global Bronchiectasis Drugs by: Indication (Value)
        • 7.2.2.1. Cylindrical Bronchiectasis
        • 7.2.2.2. Varicose Bronchiectasis
        • 7.2.2.3. Cystic Bronchiectasis
      • 7.2.3. Global Bronchiectasis Drugs by: Distribution (Value)
        • 7.2.3.1. Third Party Websites
        • 7.2.3.2. Hospital Dispensaries
        • 7.2.3.3. Retail Pharmacies
      • 7.2.4. Global Bronchiectasis Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bronchiectasis Drugs: by Type(USD Million)
  • Table 2. Bronchiectasis Drugs Antibiotics , by Region USD Million (2014-2019)
  • Table 3. Bronchiectasis Drugs Expectorants , by Region USD Million (2014-2019)
  • Table 4. Bronchiectasis Drugs Beta-Agonists , by Region USD Million (2014-2019)
  • Table 5. Bronchiectasis Drugs Inhaled Corticosteroids , by Region USD Million (2014-2019)
  • Table 6. Bronchiectasis Drugs Others , by Region USD Million (2014-2019)
  • Table 7. Bronchiectasis Drugs: by Indication(USD Million)
  • Table 8. Bronchiectasis Drugs Cylindrical Bronchiectasis , by Region USD Million (2014-2019)
  • Table 9. Bronchiectasis Drugs Varicose Bronchiectasis , by Region USD Million (2014-2019)
  • Table 10. Bronchiectasis Drugs Cystic Bronchiectasis , by Region USD Million (2014-2019)
  • Table 11. Bronchiectasis Drugs: by Distribution(USD Million)
  • Table 12. Bronchiectasis Drugs Third Party Websites , by Region USD Million (2014-2019)
  • Table 13. Bronchiectasis Drugs Hospital Dispensaries , by Region USD Million (2014-2019)
  • Table 14. Bronchiectasis Drugs Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 15. South America Bronchiectasis Drugs, by Country USD Million (2014-2019)
  • Table 16. South America Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 17. South America Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 18. South America Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 19. Brazil Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 20. Brazil Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 21. Brazil Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 22. Argentina Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 23. Argentina Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 24. Argentina Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 25. Rest of South America Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 26. Rest of South America Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 27. Rest of South America Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 28. Asia Pacific Bronchiectasis Drugs, by Country USD Million (2014-2019)
  • Table 29. Asia Pacific Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 30. Asia Pacific Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 31. Asia Pacific Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 32. China Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 33. China Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 34. China Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 35. Japan Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 36. Japan Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 37. Japan Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 38. India Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 39. India Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 40. India Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 41. South Korea Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 42. South Korea Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 43. South Korea Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 44. Taiwan Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 45. Taiwan Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 46. Taiwan Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 47. Australia Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 48. Australia Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 49. Australia Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 53. Europe Bronchiectasis Drugs, by Country USD Million (2014-2019)
  • Table 54. Europe Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 55. Europe Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 56. Europe Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 57. Germany Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 58. Germany Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 59. Germany Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 60. France Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 61. France Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 62. France Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 63. Italy Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 64. Italy Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 65. Italy Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 66. United Kingdom Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 67. United Kingdom Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 68. United Kingdom Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 69. Netherlands Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 70. Netherlands Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 71. Netherlands Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 72. Rest of Europe Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 73. Rest of Europe Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 74. Rest of Europe Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 75. MEA Bronchiectasis Drugs, by Country USD Million (2014-2019)
  • Table 76. MEA Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 77. MEA Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 78. MEA Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 79. Middle East Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 80. Middle East Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 81. Middle East Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 82. Africa Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 83. Africa Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 84. Africa Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 85. North America Bronchiectasis Drugs, by Country USD Million (2014-2019)
  • Table 86. North America Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 87. North America Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 88. North America Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 89. United States Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 90. United States Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 91. United States Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 92. Canada Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 93. Canada Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 94. Canada Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 95. Mexico Bronchiectasis Drugs, by Type USD Million (2014-2019)
  • Table 96. Mexico Bronchiectasis Drugs, by Indication USD Million (2014-2019)
  • Table 97. Mexico Bronchiectasis Drugs, by Distribution USD Million (2014-2019)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Bronchiectasis Drugs: by Type(USD Million)
  • Table 110. Bronchiectasis Drugs Antibiotics , by Region USD Million (2021-2026)
  • Table 111. Bronchiectasis Drugs Expectorants , by Region USD Million (2021-2026)
  • Table 112. Bronchiectasis Drugs Beta-Agonists , by Region USD Million (2021-2026)
  • Table 113. Bronchiectasis Drugs Inhaled Corticosteroids , by Region USD Million (2021-2026)
  • Table 114. Bronchiectasis Drugs Others , by Region USD Million (2021-2026)
  • Table 115. Bronchiectasis Drugs: by Indication(USD Million)
  • Table 116. Bronchiectasis Drugs Cylindrical Bronchiectasis , by Region USD Million (2021-2026)
  • Table 117. Bronchiectasis Drugs Varicose Bronchiectasis , by Region USD Million (2021-2026)
  • Table 118. Bronchiectasis Drugs Cystic Bronchiectasis , by Region USD Million (2021-2026)
  • Table 119. Bronchiectasis Drugs: by Distribution(USD Million)
  • Table 120. Bronchiectasis Drugs Third Party Websites , by Region USD Million (2021-2026)
  • Table 121. Bronchiectasis Drugs Hospital Dispensaries , by Region USD Million (2021-2026)
  • Table 122. Bronchiectasis Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 123. South America Bronchiectasis Drugs, by Country USD Million (2021-2026)
  • Table 124. South America Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 125. South America Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 126. South America Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 127. Brazil Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 128. Brazil Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 129. Brazil Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 130. Argentina Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 131. Argentina Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 132. Argentina Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 133. Rest of South America Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 134. Rest of South America Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 135. Rest of South America Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 136. Asia Pacific Bronchiectasis Drugs, by Country USD Million (2021-2026)
  • Table 137. Asia Pacific Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 138. Asia Pacific Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 139. Asia Pacific Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 140. China Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 141. China Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 142. China Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 143. Japan Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 144. Japan Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 145. Japan Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 146. India Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 147. India Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 148. India Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 149. South Korea Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 150. South Korea Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 151. South Korea Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 152. Taiwan Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 153. Taiwan Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 154. Taiwan Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 155. Australia Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 156. Australia Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 157. Australia Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 161. Europe Bronchiectasis Drugs, by Country USD Million (2021-2026)
  • Table 162. Europe Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 163. Europe Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 164. Europe Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 165. Germany Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 166. Germany Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 167. Germany Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 168. France Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 169. France Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 170. France Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 171. Italy Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 172. Italy Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 173. Italy Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 174. United Kingdom Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 175. United Kingdom Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 176. United Kingdom Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 177. Netherlands Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 178. Netherlands Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 179. Netherlands Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 180. Rest of Europe Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 181. Rest of Europe Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 182. Rest of Europe Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 183. MEA Bronchiectasis Drugs, by Country USD Million (2021-2026)
  • Table 184. MEA Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 185. MEA Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 186. MEA Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 187. Middle East Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 188. Middle East Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 189. Middle East Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 190. Africa Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 191. Africa Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 192. Africa Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 193. North America Bronchiectasis Drugs, by Country USD Million (2021-2026)
  • Table 194. North America Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 195. North America Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 196. North America Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 197. United States Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 198. United States Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 199. United States Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 200. Canada Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 201. Canada Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 202. Canada Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 203. Mexico Bronchiectasis Drugs, by Type USD Million (2021-2026)
  • Table 204. Mexico Bronchiectasis Drugs, by Indication USD Million (2021-2026)
  • Table 205. Mexico Bronchiectasis Drugs, by Distribution USD Million (2021-2026)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bronchiectasis Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Bronchiectasis Drugs: by Indication USD Million (2014-2019)
  • Figure 6. Global Bronchiectasis Drugs: by Distribution USD Million (2014-2019)
  • Figure 7. South America Bronchiectasis Drugs Share (%), by Country
  • Figure 8. Asia Pacific Bronchiectasis Drugs Share (%), by Country
  • Figure 9. Europe Bronchiectasis Drugs Share (%), by Country
  • Figure 10. MEA Bronchiectasis Drugs Share (%), by Country
  • Figure 11. North America Bronchiectasis Drugs Share (%), by Country
  • Figure 12. Global Bronchiectasis Drugs share by Players 2019 (%)
  • Figure 13. Global Bronchiectasis Drugs share by Players (Top 3) 2019(%)
  • Figure 14. Global Bronchiectasis Drugs share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Endo International Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Endo International Plc (Ireland) Revenue: by Geography 2019
  • Figure 18. Reckitt Benckiser Group Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Reckitt Benckiser Group Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 22. Neopharma LLC (United Arab Emirates) Revenue, Net Income and Gross profit
  • Figure 23. Neopharma LLC (United Arab Emirates) Revenue: by Geography 2019
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Santhera Pharmaceuticals Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Santhera Pharmaceuticals Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 28. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 30. Insmed Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Insmed Inc. (United States) Revenue: by Geography 2019
  • Figure 32. Aradigm Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Aradigm Corp. (United States) Revenue: by Geography 2019
  • Figure 34. Zambon S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 35. Zambon S.p.A. (Italy) Revenue: by Geography 2019
  • Figure 36. Alitair Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Alitair Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 38. Global Bronchiectasis Drugs: by Type USD Million (2021-2026)
  • Figure 39. Global Bronchiectasis Drugs: by Indication USD Million (2021-2026)
  • Figure 40. Global Bronchiectasis Drugs: by Distribution USD Million (2021-2026)
  • Figure 41. South America Bronchiectasis Drugs Share (%), by Country
  • Figure 42. Asia Pacific Bronchiectasis Drugs Share (%), by Country
  • Figure 43. Europe Bronchiectasis Drugs Share (%), by Country
  • Figure 44. MEA Bronchiectasis Drugs Share (%), by Country
  • Figure 45. North America Bronchiectasis Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Endo International Plc (Ireland)
  • Reckitt Benckiser Group Plc (United Kingdom)
  • GlaxoSmithKline Plc (United Kingdom)
  • Neopharma LLC (United Arab Emirates)
  • Pfizer Inc. (United States)
  • Santhera Pharmaceuticals Holding AG (Switzerland)
  • Bayer AG (Germany)
  • Insmed Inc. (United States)
  • Aradigm Corp. (United States)
  • Zambon S.p.A. (Italy)
  • Alitair Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation